Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration
Sign Up to like & getrecommendations! Published in 2018 at "International Ophthalmology"
DOI: 10.1007/s10792-018-0833-2
Abstract: PurposeTo compare the efficacy and safety of two intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents, ranibizumab and aflibercept, for the treatment of vascularized pigment epithelium detachment (vPED) due to age-related macular degeneration (AMD) in a… read more here.
Keywords: aflibercept treatment; treatment vascularized; ranibizumab; vascularized pigment ... See more keywords
Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
Sign Up to like & getrecommendations! Published in 2017 at "Eye"
DOI: 10.1038/eye.2017.143
Abstract: PurposeTo examine 12-month real-world visual acuity outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes, including those with pigment epithelial detachment (PED), receiving ranibizumab or aflibercept.Patients and methodsElectronic medical records were used to… read more here.
Keywords: real world; aflibercept treatment; ranibizumab; ranibizumab aflibercept ... See more keywords
Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study
Sign Up to like & getrecommendations! Published in 2022 at "Acta Ophthalmologica"
DOI: 10.1111/aos.15214
Abstract: To evaluate mean change in best‐corrected visual acuity (BCVA) at 52 weeks in patients with inflammatory choroidal neovascularization (CNV) treated with aflibercept. read more here.
Keywords: inflammatory choroidal; safety aflibercept; aflibercept treatment; choroidal neovascularization ... See more keywords
Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results.
Sign Up to like & getrecommendations! Published in 2021 at "Arquivos brasileiros de oftalmologia"
DOI: 10.5935/0004-2749.20210036
Abstract: PURPOSE This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at… read more here.
Keywords: aflibercept treatment; age related; related macular; treatment ... See more keywords